Bristol-Myers Squibb: #1 In Big Pharma

In our review of big pharma stocks, Bristol-Myers Squibb is our top rated stock, with a five-year annual expected return of 14.0%. The company is a leading drug maker of cardiovascular therapeutics, with annual revenues of about $42 billion.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.